Morepen Labs: नवाचार, विस्तार, और सेहतमंद भविष्य की ओर दृढ़ कदम

Morepen Laboratories Ltd – Technical & Fundamental Analysis Indicators: Moving averages (daily): All short-term and long-term MAs indicate a strong sell with at least 12 sell signals and none for buy. RSI (14): 20.9, in deep oversold territory —

may hint at a potential technical bounce, but weakness persists.​ MACD & Bollinger Bands: Bearish momentum, below the mean on both week and month charts; moderate trend strength, underperformance versus the Sensex.​ Price Zone: As of Nov 7, 2025, closing near ₹47. Key support at ₹45–46; resistance at ₹49.50–₹51. Outlook: Only risk-tolerant traders should consider accumulating near ₹45–46 with a tight stop; otherwise, trend remains down until a clear reversal above ₹51.​ Fundamental Analysis Q1–Q2 FY26 Results: Revenue: Around ₹425 crore quarterly (7.4% YoY growth); TTM revenue ~₹1,782 crore, positive but slowing.​ Net Profit: Q4 FY25 saw a 29% YoY drop to ₹20.3 crore due to margin pressures and input costs; yearly bottomline trend still positive but volatile.​ Valuation: P/E ~28.3 (TTM), considered high for current earnings and sector comps.​ ROCE: 12.8%; Book value per share: ₹41.6; P/B: 2.23 indicates moderate premium. Upcoming News/Events & Impact Board Meeting – 14 Nov 2025: Likely to review H1 and Q2 FY26 earnings and consider new capex/expansion news; potential for stock movement based on profit outlook.​ R&D pipeline: New launches in anti-diabetic/orthopedics. Any big US regulatory or export update could act as a near-term trigger.​ Strategic Investments: ₹200 crore QIP recently raised for expansion in APIs and devices, enhancing future growth prospects.